Refine by
Therapeutic Antibody Articles & Analysis
66 news found
l RMT-Targeting Vector Optimization and Validation Services: With extensive in silico/computational analyses and mechanism-based peptide optimization, Ace Therapeutics can generate RMT-targeting antibody or peptide variants with a broad range of biological properties. ...
This platform provides biopharmaceutical companies with a structured and regulatory-compliant approach to develop stable cell lines for therapeutic proteins, monoclonal antibodies, and other biologics. The cell line development platform leverages multiple host cell lines to increase flexibility and performance. ...
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. ...
Its end-to-end rare disease therapy development solutions cover a full package of therapeutic development services, which include small molecule, cell therapy, gene therapy, therapeutic antibody, therapeutic peptide, and therapeutic protein. ...
Another hot topic during the festival was the growing interest in single domain antibodies—also known as sdAbs. Unlike traditional antibodies, sdAbs are much smaller, making them more versatile and efficient for use in therapeutics, imaging, and diagnostics. ...
The company has introduced a state-of-the-art approach to enhance the precision and efficiency of delivering therapeutic antibodies directly to targeted sites, aiming to boost therapeutic efficacy while reducing unwanted side effects. ...
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
Precision Targeting: The technology allows for the precise targeting of disease-related molecules by understanding the intricate interactions between antibodies and antigens, minimizing off-target effects and improving therapeutic outcomes. 3. ...
Animal Extracts: The company takes pride in its assortment of Animal Extracts, responsibly sourced and invaluable in various research, diagnostic, and therapeutic applications. From antibodies to enzymes, these extracts play a pivotal role in advancing scientific and medical frontiers, underscoring Creative Enzymes' commitment to impactful biotechnology. 3. ...
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. ...
Our intent is to deliver a novel therapeutic strategy to meet the major unmet need for new treatments in Alzheimer’s and related ...
(NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,545,238, entitled “Machine Learning Method For Protein Modelling To Design Engineered Peptides,” which covers a machine learning model developed to ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and Society for Neuroscience’s ...
(Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th of ...
Although it can be argued that therapeutic antibody development relies on semi-random search-and-selection methods, such as phage display and biopanning, there is an increasingly important role played by structure-based design. ...
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022 DAEJEON, South Korea, October 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, ...
Through the support of our two recent NIH awards and our world-class investor consortium, we are excited by the potential to bring a novel therapeutic option to the millions of patients with AD and other neurodegenerative ...
(KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that it signed an MoU (Memorandum of Understanding) with FutureChem Co., Ltd. ...
Pharmaceutical enterprises have been confronted with numerous challenges, such as rising cost pressures and uncertainty in the upstream supply of APIs, antibodies, enzymes, therapeutic proteins, etc. BOC Sciences, featured with a comprehensive fermentation platform, is able to lift them out of the plight by culturing diverse microbial strains (usually fungi and ...